The isopeptidase USP2a protects human prostate cancer from apoptosis

Carmen Priolo, Dan Tang, Mohan Brahamandan, Barbara Benassi, Ewa Sicinska, Shuji Ogino, Antonella Farsetti, Alessandro Porrello, Stephen Finn, Johann Zimmermann, Phillip Febbo, Massinio Loda

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Deubiquitinating enzymes can prevent the destruction of protein substrates prior to proteasomal degradation. The ubiquitin-specific protease 2a (USP2a) deubiquitinates the antiapoptotic proteins Fatty Acid Synthase and Mdm2. Here, we show that when USP2a is overexpressed in nontransformed cells, it exhibits oncogenic behavior both in vitro and in vivo and prevents apoptosis induced by chemotherapeutic agents. Notably, USP2a silencing in several human cancer cell lines results in apoptosis. Gene set enrichment analysis, which focuses on groups of genes sharing biological function or regulatory pathways, was done on microarray expression data from human prostate cancers. The cell death-related gene set, as well as a selected cluster of validated p53 target genes, were significantly enriched in the low USP2a expression group of tumors. Conversely, genes implicated in fatty acid metabolism were significantly associated with tumors expressing high USP2a (44%). The expression profile analysis is consistent with the effects of USP2a on its known targets, i.e., Fatty Acid Synthase and Mdm2, defining a subset of prostate tumors resistant to apoptosis. USP2a thus represents a therapeutic target in prostate cancer.

Original languageEnglish
Pages (from-to)8625-8632
Number of pages8
JournalCancer Research
Volume66
Issue number17
DOIs
Publication statusPublished - Sep 1 2006

Fingerprint

Ubiquitin-Specific Proteases
Prostatic Neoplasms
Apoptosis
Fatty Acid Synthases
Genes
Neoplasms
p53 Genes
isopeptidase
Focus Groups
Prostate
Proteins
Cell Death
Fatty Acids
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Priolo, C., Tang, D., Brahamandan, M., Benassi, B., Sicinska, E., Ogino, S., ... Loda, M. (2006). The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Research, 66(17), 8625-8632. https://doi.org/10.1158/0008-5472.CAN-06-1374

The isopeptidase USP2a protects human prostate cancer from apoptosis. / Priolo, Carmen; Tang, Dan; Brahamandan, Mohan; Benassi, Barbara; Sicinska, Ewa; Ogino, Shuji; Farsetti, Antonella; Porrello, Alessandro; Finn, Stephen; Zimmermann, Johann; Febbo, Phillip; Loda, Massinio.

In: Cancer Research, Vol. 66, No. 17, 01.09.2006, p. 8625-8632.

Research output: Contribution to journalArticle

Priolo, C, Tang, D, Brahamandan, M, Benassi, B, Sicinska, E, Ogino, S, Farsetti, A, Porrello, A, Finn, S, Zimmermann, J, Febbo, P & Loda, M 2006, 'The isopeptidase USP2a protects human prostate cancer from apoptosis', Cancer Research, vol. 66, no. 17, pp. 8625-8632. https://doi.org/10.1158/0008-5472.CAN-06-1374
Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S et al. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Research. 2006 Sep 1;66(17):8625-8632. https://doi.org/10.1158/0008-5472.CAN-06-1374
Priolo, Carmen ; Tang, Dan ; Brahamandan, Mohan ; Benassi, Barbara ; Sicinska, Ewa ; Ogino, Shuji ; Farsetti, Antonella ; Porrello, Alessandro ; Finn, Stephen ; Zimmermann, Johann ; Febbo, Phillip ; Loda, Massinio. / The isopeptidase USP2a protects human prostate cancer from apoptosis. In: Cancer Research. 2006 ; Vol. 66, No. 17. pp. 8625-8632.
@article{8b6d35043220496a8da5fe3918adf7f8,
title = "The isopeptidase USP2a protects human prostate cancer from apoptosis",
abstract = "Deubiquitinating enzymes can prevent the destruction of protein substrates prior to proteasomal degradation. The ubiquitin-specific protease 2a (USP2a) deubiquitinates the antiapoptotic proteins Fatty Acid Synthase and Mdm2. Here, we show that when USP2a is overexpressed in nontransformed cells, it exhibits oncogenic behavior both in vitro and in vivo and prevents apoptosis induced by chemotherapeutic agents. Notably, USP2a silencing in several human cancer cell lines results in apoptosis. Gene set enrichment analysis, which focuses on groups of genes sharing biological function or regulatory pathways, was done on microarray expression data from human prostate cancers. The cell death-related gene set, as well as a selected cluster of validated p53 target genes, were significantly enriched in the low USP2a expression group of tumors. Conversely, genes implicated in fatty acid metabolism were significantly associated with tumors expressing high USP2a (44{\%}). The expression profile analysis is consistent with the effects of USP2a on its known targets, i.e., Fatty Acid Synthase and Mdm2, defining a subset of prostate tumors resistant to apoptosis. USP2a thus represents a therapeutic target in prostate cancer.",
author = "Carmen Priolo and Dan Tang and Mohan Brahamandan and Barbara Benassi and Ewa Sicinska and Shuji Ogino and Antonella Farsetti and Alessandro Porrello and Stephen Finn and Johann Zimmermann and Phillip Febbo and Massinio Loda",
year = "2006",
month = "9",
day = "1",
doi = "10.1158/0008-5472.CAN-06-1374",
language = "English",
volume = "66",
pages = "8625--8632",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - The isopeptidase USP2a protects human prostate cancer from apoptosis

AU - Priolo, Carmen

AU - Tang, Dan

AU - Brahamandan, Mohan

AU - Benassi, Barbara

AU - Sicinska, Ewa

AU - Ogino, Shuji

AU - Farsetti, Antonella

AU - Porrello, Alessandro

AU - Finn, Stephen

AU - Zimmermann, Johann

AU - Febbo, Phillip

AU - Loda, Massinio

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Deubiquitinating enzymes can prevent the destruction of protein substrates prior to proteasomal degradation. The ubiquitin-specific protease 2a (USP2a) deubiquitinates the antiapoptotic proteins Fatty Acid Synthase and Mdm2. Here, we show that when USP2a is overexpressed in nontransformed cells, it exhibits oncogenic behavior both in vitro and in vivo and prevents apoptosis induced by chemotherapeutic agents. Notably, USP2a silencing in several human cancer cell lines results in apoptosis. Gene set enrichment analysis, which focuses on groups of genes sharing biological function or regulatory pathways, was done on microarray expression data from human prostate cancers. The cell death-related gene set, as well as a selected cluster of validated p53 target genes, were significantly enriched in the low USP2a expression group of tumors. Conversely, genes implicated in fatty acid metabolism were significantly associated with tumors expressing high USP2a (44%). The expression profile analysis is consistent with the effects of USP2a on its known targets, i.e., Fatty Acid Synthase and Mdm2, defining a subset of prostate tumors resistant to apoptosis. USP2a thus represents a therapeutic target in prostate cancer.

AB - Deubiquitinating enzymes can prevent the destruction of protein substrates prior to proteasomal degradation. The ubiquitin-specific protease 2a (USP2a) deubiquitinates the antiapoptotic proteins Fatty Acid Synthase and Mdm2. Here, we show that when USP2a is overexpressed in nontransformed cells, it exhibits oncogenic behavior both in vitro and in vivo and prevents apoptosis induced by chemotherapeutic agents. Notably, USP2a silencing in several human cancer cell lines results in apoptosis. Gene set enrichment analysis, which focuses on groups of genes sharing biological function or regulatory pathways, was done on microarray expression data from human prostate cancers. The cell death-related gene set, as well as a selected cluster of validated p53 target genes, were significantly enriched in the low USP2a expression group of tumors. Conversely, genes implicated in fatty acid metabolism were significantly associated with tumors expressing high USP2a (44%). The expression profile analysis is consistent with the effects of USP2a on its known targets, i.e., Fatty Acid Synthase and Mdm2, defining a subset of prostate tumors resistant to apoptosis. USP2a thus represents a therapeutic target in prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=33746820622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746820622&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-1374

DO - 10.1158/0008-5472.CAN-06-1374

M3 - Article

VL - 66

SP - 8625

EP - 8632

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 17

ER -